GENETEC TECHNOLOGY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.91 MYR | +0.53% |
|
+3.24% | -19.07% |
| Feb. 27 | Genetec Technology Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| 2023 | Genetec Technology's Profit Drops in September Quarter | MT |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 194 | 1,719 | 2,025 | 1,481 | - | - |
| Enterprise Value (EV) 1 | 194 | 1,781 | 1,896 | 1,472 | 1,388 | 1,288 |
| P/E ratio | -43.7 x | 31.9 x | 26.6 x | 14.1 x | 12.7 x | 10.9 x |
| Yield | - | - | - | 1.1% | 1.15% | 1.36% |
| Capitalization / Revenue | 2 x | 7.69 x | 6.59 x | 3.54 x | 3.18 x | 2.8 x |
| EV / Revenue | 2 x | 7.97 x | 6.17 x | 3.52 x | 2.98 x | 2.44 x |
| EV / EBITDA | - | 26.5 x | 21.8 x | 11.7 x | 9.84 x | 7.89 x |
| EV / FCF | - | -16.5 x | 122 x | 35.2 x | 15.5 x | 12.4 x |
| FCF Yield | - | -6.05% | 0.82% | 2.84% | 6.43% | 8.04% |
| Price to Book | - | 11.5 x | 5 x | 2.88 x | 2.39 x | 1.99 x |
| Nbr of stocks (in thousands) | 593,311 | 681,962 | 750,158 | 775,131 | - | - |
| Reference price 2 | 0.3269 | 2.520 | 2.700 | 1.910 | 1.910 | 1.910 |
| Announcement Date | 7/29/21 | 5/26/22 | 5/31/23 | - | - | - |
1MYR in Million2MYR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 97.08 | 223.6 | 307.4 | 418 | 464.8 | 528.2 |
| EBITDA 1 | - | 67.2 | 86.87 | 125.3 | 141 | 163.2 |
| EBIT 1 | - | 63.93 | 83.32 | 114.6 | 128.5 | 149.9 |
| Operating Margin | - | 28.59% | 27.1% | 27.42% | 27.64% | 28.38% |
| Earnings before Tax (EBT) 1 | - | 62.29 | 80.3 | 112.4 | 127.2 | 149.9 |
| Net income 1 | - | 56.4 | 73.4 | 101.5 | 111.1 | 130.2 |
| Net margin | - | 25.23% | 23.88% | 24.29% | 23.91% | 24.65% |
| EPS 2 | -0.007480 | 0.0790 | 0.1015 | 0.1354 | 0.1501 | 0.1757 |
| Free Cash Flow 1 | - | -107.7 | 15.58 | 41.76 | 89.27 | 103.6 |
| FCF margin | - | -48.19% | 5.07% | 9.99% | 19.2% | 19.61% |
| FCF Conversion (EBITDA) | - | - | 17.93% | 33.33% | 63.31% | 63.44% |
| FCF Conversion (Net income) | - | - | 21.22% | 41.13% | 80.32% | 79.53% |
| Dividend per Share 2 | - | - | - | 0.0210 | 0.0220 | 0.0260 |
| Announcement Date | 7/29/21 | 5/26/22 | 5/31/23 | - | - | - |
1MYR in Million2MYR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 62.6 | - | - | - | - |
| Net Cash position 1 | - | - | 130 | 8.97 | 93 | 193 |
| Leverage (Debt/EBITDA) | - | 0.932 x | - | - | - | - |
| Free Cash Flow 1 | - | -108 | 15.6 | 41.8 | 89.3 | 104 |
| ROE (net income / shareholders' equity) | - | 49% | 26.4% | 22.5% | 20.2% | 19.7% |
| ROA (Net income/ Total Assets) | - | 27% | 18.1% | 19.4% | 18.3% | 18.2% |
| Assets 1 | - | 209.3 | 405.7 | 523.4 | 606.9 | 716.8 |
| Book Value Per Share 2 | - | 0.2200 | 0.5400 | 0.6600 | 0.8000 | 0.9600 |
| Cash Flow per Share 2 | - | -0.1400 | 0.1300 | 0.0900 | 0.1300 | 0.1500 |
| Capex 1 | - | 8.13 | 76.8 | 30 | 10 | 10 |
| Capex / Sales | - | 3.64% | 24.98% | 7.18% | 2.15% | 1.89% |
| Announcement Date | 7/29/21 | 5/26/22 | 5/31/23 | - | - | - |
1MYR in Million2MYR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.91
MYR
Average target price
4.05
MYR
Spread / Average Target
+112.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.07% | 311M | |
| +11.73% | 82.35B | |
| +20.17% | 71.09B | |
| +20.89% | 37.72B | |
| +15.77% | 32.01B | |
| +9.19% | 27.2B | |
| +3.18% | 26.74B | |
| +4.22% | 26B | |
| +16.93% | 25.5B | |
| +17.14% | 24.76B |
- Stock Market
- Equities
- GENETEC Stock
- Financials Genetec Technology
